{"id":48915,"date":"2022-09-28T15:02:39","date_gmt":"2022-09-28T13:02:39","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/rob-parr-rejoins-wilson-sonsini-in-boston-as-the-firm-continues-to-expand-its-technology-transactions-department\/"},"modified":"2022-09-28T15:02:39","modified_gmt":"2022-09-28T13:02:39","slug":"rob-parr-rejoins-wilson-sonsini-in-boston-as-the-firm-continues-to-expand-its-technology-transactions-department","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/rob-parr-rejoins-wilson-sonsini-in-boston-as-the-firm-continues-to-expand-its-technology-transactions-department\/","title":{"rendered":"Rob Parr Rejoins Wilson Sonsini in Boston as the Firm Continues to Expand its Technology Transactions Department"},"content":{"rendered":"
\n

\nAddition Reflects the Continued Growth of the Boston Office and Sustained Demand for Transactional Experience Among Technology and Life Sciences Clients<\/i><\/b>\n<\/p>\n

\nWilson Sonsini Recently Added Seth Flaum in New York as a Partner in the Technology Transactions Department<\/i><\/b>\n<\/p>\n

PALO ALTO, Calif.–(BUSINESS WIRE)–Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life sciences, and growth enterprises worldwide, announced today that Rob Parr<\/b><\/a> <\/b>has rejoined the firm\u2019s technology transactions department as a partner in the Boston office. His return reflects Wilson Sonsini\u2019s continued growth in Boston and the ongoing demand for tech-driven deal experience.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nParr has advised clients at all stages of growth on transactions focused on IP rights and technology across various industries, including digital health, artificial intelligence, autonomous driving, big data, clean energy, cloud computing, digital media, e-commerce, edtech, fintech, gaming, internet of things, and software. He regularly drafts and negotiates complex commercial contracts and assists clients with the IP issues arising in financings and M&A deals.\n<\/p>\n

\nParr also has substantial expertise that will fortify Wilson Sonsini\u2019s digital health practice, which is a multi-disciplinary group that represents clients in the many areas vital to their businesses, such as with corporate, privacy and data security, intellectual property, commercial transactions, FDA\/regulatory and litigation matters.\n<\/p>\n

\n\u201cWe\u2019ve seen continued demand for a combination of transactional and industry experience that helps clients proceed with deal-making and ongoing business matters, even in what is a less active market in certain sectors,\u201d said Doug Clark<\/b>, managing partner at Wilson Sonsini. \u201cRob is accustomed to working with clients in dynamic industries that need his commercial and deal-related experience, and to that we add our firm\u2019s strengths representing companies and investors in Boston, the Northeast, and nationwide. We\u2019re pleased he\u2019s returned to our firm.\u201d\n<\/p>\n

\nPrior to rejoining the firm, Parr was a partner at Orrick, Herrington & Sutcliffe. Before that, he worked in Wilson Sonsini\u2019s technology transactions department. He joined the firm\u2019s Washington, D.C., office as an associate in 2015 before relocating to the Boston office in 2019 and becoming Of Counsel in May 2021. Upon graduating from law school in 2012, Parr was an associate in Venable\u2019s Washington, D.C., office before joining Wilson Sonsini.\n<\/p>\n

\nParr\u2019s addition reflects the continued expansion of Wilson Sonsini\u2019s Boston office. Wilson Sonsini opened its Boston office in 2016 to be in closer proximity to its base of clients in the area\u2014many of which are innovative companies and investors in the region\u2019s vibrant life sciences and digital health communities. The firm also aimed to better serve its expanding client base in the local technology and energy sectors, as well as other emerging growth enterprises in the area. Wilson Sonsini\u2019s Boston office now has 10 partners, 29 other attorneys, and seven patent agents.\n<\/p>\n

\n\u201cI am very excited to return to Wilson Sonsini and to work with leading technology companies and their investors, and to help the firm expand its client base in Boston and beyond, including in the digital health space. I am also very excited to rejoin such an impressive and growing team in Boston, and my many friends and colleagues across the firm,\u201d said Parr.\n<\/p>\n

\nParr is the 16th<\/sup> lateral partner to join Wilson Sonsini in 2022. On August 25, 2022<\/a>, the firm announced that Seth Flaum<\/b> had joined the technology transactions department as a partner in the New York office. Flaum was previously executive associate general counsel for Daiichi Sankyo, Inc., a global pharmaceutical company based in Japan. While Parr\u2019s practice will focus on representing technology clients, Flaum specializes in representing life sciences clients.\n<\/p>\n

\nParr earned his J.D. from George Washington University Law School in 2012. He is admitted to practice in the District of Columbia, Maryland, and Massachusetts.\n<\/p>\n

\nAbout Wilson Sonsini Goodrich & Rosati<\/i>\n<\/p>\n

\nFor more than 60 years, Wilson Sonsini\u2019s services and legal disciplines have focused on serving the principal challenges faced by the management and boards of directors of business enterprises. The firm is nationally recognized as a leading provider to growing and established clients seeking legal counsel to complete sophisticated corporate and technology transactions; manage governance and enterprise-scale matters; assist with intellectual property development, protection, and IP-driven transactions; represent them in contested disputes; and\/or advise them on antitrust or other regulatory matters. With deep roots in Silicon Valley, Wilson Sonsini has offices in 18 technology and business hubs worldwide. For more information, please visit www.wsgr.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nWayne Kessler
\n
Baretz+Brunelle
\n
732.239.9710 Mobile
\n
wkessler@baretzbrunelle.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Addition Reflects the Continued Growth of the Boston Office and Sustained Demand for Transactional Experience Among Technology and Life Sciences Clients Wilson Sonsini Recently Added Seth Flaum in New York as a Partner in the Technology Transactions Department PALO ALTO, Calif.–(BUSINESS WIRE)–Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48915","6":"format-standard","7":"category-industry"},"yoast_head":"\nRob Parr Rejoins Wilson Sonsini in Boston as the Firm Continues to Expand its Technology Transactions Department - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/rob-parr-rejoins-wilson-sonsini-in-boston-as-the-firm-continues-to-expand-its-technology-transactions-department\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rob Parr Rejoins Wilson Sonsini in Boston as the Firm Continues to Expand its Technology Transactions Department - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Addition Reflects the Continued Growth of the Boston Office and Sustained Demand for Transactional Experience Among Technology and Life Sciences Clients Wilson Sonsini Recently Added Seth Flaum in New York as a Partner in the Technology Transactions Department PALO ALTO, Calif.–(BUSINESS WIRE)–Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/rob-parr-rejoins-wilson-sonsini-in-boston-as-the-firm-continues-to-expand-its-technology-transactions-department\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-28T13:02:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220928005187\/en\/1584644\/21\/parr_robert-hi-20170328_email.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rob-parr-rejoins-wilson-sonsini-in-boston-as-the-firm-continues-to-expand-its-technology-transactions-department\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rob-parr-rejoins-wilson-sonsini-in-boston-as-the-firm-continues-to-expand-its-technology-transactions-department\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Rob Parr Rejoins Wilson Sonsini in Boston as the Firm Continues to Expand its Technology Transactions Department\",\"datePublished\":\"2022-09-28T13:02:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rob-parr-rejoins-wilson-sonsini-in-boston-as-the-firm-continues-to-expand-its-technology-transactions-department\\\/\"},\"wordCount\":763,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rob-parr-rejoins-wilson-sonsini-in-boston-as-the-firm-continues-to-expand-its-technology-transactions-department\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220928005187\\\/en\\\/1584644\\\/21\\\/parr_robert-hi-20170328_email.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rob-parr-rejoins-wilson-sonsini-in-boston-as-the-firm-continues-to-expand-its-technology-transactions-department\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rob-parr-rejoins-wilson-sonsini-in-boston-as-the-firm-continues-to-expand-its-technology-transactions-department\\\/\",\"name\":\"Rob Parr Rejoins Wilson Sonsini in Boston as the Firm Continues to Expand its Technology Transactions Department - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rob-parr-rejoins-wilson-sonsini-in-boston-as-the-firm-continues-to-expand-its-technology-transactions-department\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rob-parr-rejoins-wilson-sonsini-in-boston-as-the-firm-continues-to-expand-its-technology-transactions-department\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220928005187\\\/en\\\/1584644\\\/21\\\/parr_robert-hi-20170328_email.jpg\",\"datePublished\":\"2022-09-28T13:02:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rob-parr-rejoins-wilson-sonsini-in-boston-as-the-firm-continues-to-expand-its-technology-transactions-department\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rob-parr-rejoins-wilson-sonsini-in-boston-as-the-firm-continues-to-expand-its-technology-transactions-department\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rob-parr-rejoins-wilson-sonsini-in-boston-as-the-firm-continues-to-expand-its-technology-transactions-department\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220928005187\\\/en\\\/1584644\\\/21\\\/parr_robert-hi-20170328_email.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220928005187\\\/en\\\/1584644\\\/21\\\/parr_robert-hi-20170328_email.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rob-parr-rejoins-wilson-sonsini-in-boston-as-the-firm-continues-to-expand-its-technology-transactions-department\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rob Parr Rejoins Wilson Sonsini in Boston as the Firm Continues to Expand its Technology Transactions Department\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rob Parr Rejoins Wilson Sonsini in Boston as the Firm Continues to Expand its Technology Transactions Department - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/rob-parr-rejoins-wilson-sonsini-in-boston-as-the-firm-continues-to-expand-its-technology-transactions-department\/","og_locale":"en_US","og_type":"article","og_title":"Rob Parr Rejoins Wilson Sonsini in Boston as the Firm Continues to Expand its Technology Transactions Department - Pharma Trend","og_description":"Addition Reflects the Continued Growth of the Boston Office and Sustained Demand for Transactional Experience Among Technology and Life Sciences Clients Wilson Sonsini Recently Added Seth Flaum in New York as a Partner in the Technology Transactions Department PALO ALTO, Calif.–(BUSINESS WIRE)–Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/rob-parr-rejoins-wilson-sonsini-in-boston-as-the-firm-continues-to-expand-its-technology-transactions-department\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-28T13:02:39+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220928005187\/en\/1584644\/21\/parr_robert-hi-20170328_email.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/rob-parr-rejoins-wilson-sonsini-in-boston-as-the-firm-continues-to-expand-its-technology-transactions-department\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/rob-parr-rejoins-wilson-sonsini-in-boston-as-the-firm-continues-to-expand-its-technology-transactions-department\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Rob Parr Rejoins Wilson Sonsini in Boston as the Firm Continues to Expand its Technology Transactions Department","datePublished":"2022-09-28T13:02:39+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/rob-parr-rejoins-wilson-sonsini-in-boston-as-the-firm-continues-to-expand-its-technology-transactions-department\/"},"wordCount":763,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/rob-parr-rejoins-wilson-sonsini-in-boston-as-the-firm-continues-to-expand-its-technology-transactions-department\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220928005187\/en\/1584644\/21\/parr_robert-hi-20170328_email.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/rob-parr-rejoins-wilson-sonsini-in-boston-as-the-firm-continues-to-expand-its-technology-transactions-department\/","url":"https:\/\/pharma-trend.com\/en\/rob-parr-rejoins-wilson-sonsini-in-boston-as-the-firm-continues-to-expand-its-technology-transactions-department\/","name":"Rob Parr Rejoins Wilson Sonsini in Boston as the Firm Continues to Expand its Technology Transactions Department - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/rob-parr-rejoins-wilson-sonsini-in-boston-as-the-firm-continues-to-expand-its-technology-transactions-department\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/rob-parr-rejoins-wilson-sonsini-in-boston-as-the-firm-continues-to-expand-its-technology-transactions-department\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220928005187\/en\/1584644\/21\/parr_robert-hi-20170328_email.jpg","datePublished":"2022-09-28T13:02:39+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/rob-parr-rejoins-wilson-sonsini-in-boston-as-the-firm-continues-to-expand-its-technology-transactions-department\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/rob-parr-rejoins-wilson-sonsini-in-boston-as-the-firm-continues-to-expand-its-technology-transactions-department\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/rob-parr-rejoins-wilson-sonsini-in-boston-as-the-firm-continues-to-expand-its-technology-transactions-department\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220928005187\/en\/1584644\/21\/parr_robert-hi-20170328_email.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220928005187\/en\/1584644\/21\/parr_robert-hi-20170328_email.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/rob-parr-rejoins-wilson-sonsini-in-boston-as-the-firm-continues-to-expand-its-technology-transactions-department\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Rob Parr Rejoins Wilson Sonsini in Boston as the Firm Continues to Expand its Technology Transactions Department"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48915","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48915"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48915\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48915"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48915"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48915"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}